Clinical evaluation of dried blood spots for the determination of ribociclib blood levels

Clinical evaluation of dried blood spots for the determination of ribociclib blood levels - RIBO-DBS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48374

Enrollment

Registered

2019-09-26

Start date

2019-09-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borstkanker

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age * 18 years; 2. Able to understand the written information and able to give informed consent; 3. Treated with ribociclib; 4. Able and willing to undergo a finger prick for dried blood spot sampling.

Exclusion criteria

Exclusion criteria: Unable to draw blood for study purposes.

Design outcomes

Primary

Measure	Time frame
To develop and validate a dried blood spot (DBS) method for determination of ribociclib.	—

Secondary

Measure	Time frame
To characterize the pharmacokinetics of ribociclib.	—

Countries

Netherlands

Outcome results